

# Illicit Drug Use and HIV-1 Disease Progression: A Longitudinal Study of Active Antiretroviral Therapy

American Journal of Epidemiology

163, 412-420

DOI: [10.1093/aje/kwj059](https://doi.org/10.1093/aje/kwj059)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current World Literature. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 449-469.	1.5	0
2	Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 1039-1047.	0.6	39
3	Adherence, Drug Use, and Treatment Failure in a Methadone-Clinic-Based Program of Directly Administered Antiretroviral Therapy. <i>AIDS Patient Care and STDs</i> , 2007, 21, 564-574.	1.1	43
4	Optimizing Treatment Outcomes in HIV-Infected Patients with Substance Abuse Issues. <i>Clinical Infectious Diseases</i> , 2007, 45, S318-S323.	2.9	36
5	Survival of HIV-Infected Injection Drug Users (IDUs) in the Highly Active Antiretroviral Therapy Era, Relative to Sex- and Age-Specific Survival of HIV-Uninfected IDUs. <i>Clinical Infectious Diseases</i> , 2007, 45, 370-376.	2.9	28
6	Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2007, 45, 770-778.	2.9	140
7	Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 637-645.	0.6	32
8	Survival during Renal Replacement Therapy among African Americans Infected with HIV Type 1 in Urban Baltimore, Maryland. <i>Clinical Infectious Diseases</i> , 2007, 45, 1625-1632.	2.9	36
9	Improving Survival among HIV-Infected Injection Drug Users: How Should We Define Success?. <i>Clinical Infectious Diseases</i> , 2007, 45, 377-380.	2.9	11
10	Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 555-563.	0.9	15
11	Heterogeneous response to HAART across a diverse population of people living with HIV: results from the ANRS-EN12-VESPA Study. <i>Aids</i> , 2007, 21, S5-S12.	1.0	33
12	Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). <i>International Journal of Drug Policy</i> , 2007, 18, 262-270.	1.6	113
13	Antiretroviral HIV treatment and care for injecting drug users: An evidence-based overview. <i>International Journal of Drug Policy</i> , 2007, 18, 255-261.	1.6	66
14	Cigarette Smoking among HIV+ Men and Women: Examining Health, Substance Use, and Psychosocial Correlates across the Smoking Spectrum. <i>Journal of Behavioral Medicine</i> , 2007, 30, 371-383.	1.1	114
15	Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. <i>AIDS and Behavior</i> , 2008, 12, 284-293.	1.4	33
16	Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005. <i>HIV Medicine</i> , 2008, 9, 535-543.	1.0	62
17	The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. <i>Addiction</i> , 2008, 103, 1828-1836.	1.7	118
18	The changing epidemiology of prevalent diagnosed HIV infections in Taiwan, 1984-2005. <i>International Journal of Drug Policy</i> , 2008, 19, 317-323.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. <i>Aids</i> , 2008, 22, 415-420.	1.0	43
20	Short-Term Discontinuation of HAART Regimens More Common in Vulnerable Patient Populations. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1347-1355.	0.5	44
21	Structures of Care in the Clinics of the HIV Research Network. <i>AIDS Patient Care and STDs</i> , 2008, 22, 1007-1013.	1.1	43
22	The Effect of Mental Illness, Substance Use, and Treatment for Depression on the Initiation of Highly Active Antiretroviral Therapy among HIV-Infected Individuals. <i>AIDS Patient Care and STDs</i> , 2008, 22, 233-243.	1.1	183
23	Causes of Death in the Era of Highly Active Antiretroviral Therapy: A Retrospective Analysis of a Hybrid Hematology-Oncology and HIV Practice and the Seattle/King County Adult/Adolescent Spectrum of HIV-Related Diseases Project. <i>American Journal of the Medical Sciences</i> , 2008, 336, 217-223.	0.4	17
24	Illicit drug use and HIV treatment outcomes in a US cohort. <i>Aids</i> , 2008, 22, 357-365.	1.0	86
25	Medical Clinic Characteristics and Access to Behavioral Health Services for Persons With HIV. <i>Psychiatric Services</i> , 2008, 59, 400-407.	1.1	10
26	Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. <i>Aids</i> , 2008, 22, 1355-1363.	1.0	190
27	Microbial Translocation Is Associated with Increased Monocyte Activation and Dementia in AIDS Patients. <i>PLoS ONE</i> , 2008, 3, e2516.	1.1	426
28	Piloting a Peer-Driven Intervention Model to Increase Access and Adherence to Antiretroviral Therapy and HIV Care among Street-Entrenched HIV-Positive Women in Vancouver. <i>AIDS Patient Care and STDs</i> , 2009, 23, 603-609.	1.1	75
29	Drug Abuse and Hepatitis C Infection as Comorbid Features of HIV Associated Neurocognitive Disorder: Neurocognitive and Neuroimaging Features. <i>Neuropsychology Review</i> , 2009, 19, 215-231.	2.5	74
31	Morphine and HIV-1 Tat increase microglial free radical production and oxidative stress: possible role in cytokine regulation. <i>Journal of Neurochemistry</i> , 2009, 108, 202-215.	2.1	87
32	Uptake of and virological response to antiretroviral therapy among HIV-1 infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2009, 10, 407-416.	1.0	70
33	Withdrawal symptoms as a predictor of mortality in patients HIV-1 infected through drug use and receiving highly active antiretroviral therapy (HAART). <i>Drug and Alcohol Dependence</i> , 2009, 99, 96-104.	1.6	14
34	Crack-Cocaine Use Accelerates HIV Disease Progression in a Cohort of HIV-Positive Drug Users. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 93-99.	0.9	223
35	Nonstructured Treatment Interruptions Among Injection Drug Users in Baltimore, MD. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 360-366.	0.9	49
36	Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 176-181.	0.9	39
37	Early mortality and cause of deaths in patients using HAART in Brazil and the United States. <i>Aids</i> , 2009, 23, 2107-2114.	1.0	59

#	ARTICLE	IF	CITATIONS
38	Nursing Research in Tobacco Use and Special Populations. Annual Review of Nursing Research, 2009, 27, 319-342.	0.7	3
39	Drug Treatment as HIV Prevention: A Research Update. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S32-S36.	0.9	94
40	The HIV Epidemic in the United States: A Time for Action. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S63.	0.9	5
41	Antiretroviral Therapy: A Promising HIV Prevention Strategy?. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S116-S121.	0.9	23
42	Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program. Annals of Internal Medicine, 2010, 152, 704.	2.0	99
43	Drug Treatment as HIV Prevention: Expanding Treatment Options. Current HIV/AIDS Reports, 2010, 7, 220-225.	1.1	39
44	Impact of injecting drug use on mortality in Danish HIV-infected patients: a nationwide population-based cohort study. Addiction, 2010, 105, 529-535.	1.7	29
45	Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction, 2010, 105, 907-913.	1.7	125
46	Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antiviral Therapy, 2010, 15, 789-796.	0.6	19
47	Stress, Coping, and Health in HIV/AIDS. , 2010, , .		3
48	Mortality After Diagnosis of Psychiatric Disorders and Co-Occurring Substance Use Disorders Among HIV-Infected Patients. AIDS Patient Care and STDs, 2010, 24, 705-712.	1.1	56
49	Antiretroviral Use Among Active Injection-Drug Users: The Role of Patient-Provider Engagement and Structural Factors. AIDS Patient Care and STDs, 2010, 24, 421-428.	1.1	46
50	Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: A nationwide population-based cohort study. Scandinavian Journal of Infectious Diseases, 2010, 42, 917-923.	1.5	16
51	Nutrition Issues in the HIV-Infected Injection Drug User: Findings from the Nutrition for Healthy Living Cohort. Journal of the American College of Nutrition, 2010, 29, 136-143.	1.1	14
52	Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet, The, 2010, 376, 355-366.	6.3	383
53	Alcohol Use Accelerates HIV Disease Progression. AIDS Research and Human Retroviruses, 2010, 26, 511-518.	0.5	235
54	Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sciences, 2011, 88, 948-952.	2.0	62
55	Substance use and HIV disease progression in the HAART era: Implications for the primary prevention of HIV. Life Sciences, 2011, 88, 940-947.	2.0	101

#	ARTICLE	IF	CITATIONS
56	Drugs of abuse and HIV infection/replication: Implications for mother-to-fetus transmission. <i>Life Sciences</i> , 2011, 88, 972-979.	2.0	30
57	Associations between use of crack cocaine and HIV-1 disease progression: Research findings and implications for mother-to-infant transmission. <i>Life Sciences</i> , 2011, 88, 931-939.	2.0	27
58	Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy. <i>Journal of Substance Abuse Treatment</i> , 2011, 40, 386-396.	1.5	39
59	All-cause and HIV-related Mortality Rates Among HIV-infected Patients After Initiating Highly Active Antiretroviral Therapy: The Impact of Aboriginal Ethnicity and Injection Drug Use. <i>Canadian Journal of Public Health</i> , 2011, 102, 90-96.	1.1	26
60	Drug Use and Receipt of Highly Active Antiretroviral Therapy among HIV-Infected Persons in Two U.S. Clinic Cohorts. <i>PLoS ONE</i> , 2011, 6, e18462.	1.1	43
61	Excess Mortality Among HIV-Infected Patients Diagnosed With Substance Use Dependence or Abuse Receiving Care in a Fully Integrated Medical Care Program. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 203-210.	1.4	57
62	Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. <i>Psychopharmacology</i> , 2011, 215, 697-707.	1.5	31
63	Opioids and HIV/HCV Infection. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 477-489.	2.1	50
64	Homelessness and Adherence to Antiretroviral Therapy among a Cohort of HIV-Infected Injection Drug Users. <i>Journal of Urban Health</i> , 2011, 88, 545-555.	1.8	100
65	Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs. <i>BMC Infectious Diseases</i> , 2011, 11, 45.	1.3	3
66	Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. <i>BMC Infectious Diseases</i> , 2011, 11, 86.	1.3	91
67	Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 775-785.	0.6	53
68	Psychiatric Risk Factors for HIV Disease Progression: The Role of Inconsistent Patterns of Antiretroviral Therapy Utilization. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 146-150.	0.9	117
69	Cocaine Reduces Thymic Endocrine Function: Another Mechanism for Accelerated HIV Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 815-822.	0.5	23
70	Improvement in the Health of HIV-Infected Persons in Care: Reducing Disparities. <i>Clinical Infectious Diseases</i> , 2012, 55, 1242-1251.	2.9	71
71	A Systematic Review of Behavioral and Treatment Outcome Studies Among HIV-Infected Men Who Have Sex with Men Who Abuse Crystal Methamphetamine. <i>AIDS Patient Care and STDs</i> , 2012, 26, 36-52.	1.1	121
72	Young Age Predicts Poor Antiretroviral Adherence and Viral Load Suppression Among Injection Drug Users. <i>AIDS Patient Care and STDs</i> , 2012, 26, 274-280.	1.1	47
73	Relying on Injection Drug Users to Access and Adhere to HIV Therapeutics. <i>Journal of Drug Issues</i> , 2012, 42, 127-146.	0.6	7

#	ARTICLE	IF	CITATIONS
74	Pain, Mood, and Substance Abuse in HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, 164-170.	0.9	113
75	Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. <i>Drug and Alcohol Dependence</i> , 2012, 124, 108-112.	1.6	30
76	Harm reduction services as a point-of-entry to and source of end-of-life care and support for homeless and marginally housed persons who use alcohol and/or illicit drugs: a qualitative analysis. <i>BMC Public Health</i> , 2012, 12, 312.	1.2	32
78	The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. <i>HIV Medicine</i> , 2012, 13, 89-97.	1.0	53
79	An overlooked majority: HIV-positive gay men who smoke. <i>Journal of Men's Health</i> , 2012, 9, 17-24.	0.1	5
80	Psychosocial and Demographic Correlates of Drug Use in a Sample of HIV-Positive Adults Ages 50 and Older. <i>Prevention Science</i> , 2013, 14, 618-627.	1.5	20
81	Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. <i>Behavioural Brain Research</i> , 2013, 236, 210-220.	1.2	27
82	Comparison of Risk Factors and Outcomes in HIV Immune Complex Kidney Disease and HIV-Associated Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1524-1532.	2.2	62
83	Mental Health Comorbidity and HIV/AIDS. , 2013, , 9-35.		1
84	Patient Demographic and Health Factors Associated With Frequent Use of Emergency Medical Services in a Midsized City. <i>Academic Emergency Medicine</i> , 2013, 20, 1101-1111.	0.8	51
85	Coping styles and illicit drug use in older adults with HIV/AIDS.. <i>Psychology of Addictive Behaviors</i> , 2013, 27, 1050-1058.	1.4	30
86	A Conceptual Framework for Understanding Chronic Pain in Patients with HIV. <i>Pain Practice</i> , 2014, 14, 207-216.	0.9	58
87	Integrating antiretroviral therapy in methadone maintenance therapy clinics: Service provider perceptions. <i>International Journal of Drug Policy</i> , 2014, 25, 1066-1070.	1.6	18
88	Cocaine Enhances HIV-1-Induced CD4+ T-Cell Apoptosis. <i>American Journal of Pathology</i> , 2014, 184, 927-936.	1.9	32
90	Employment-based abstinence reinforcement following inpatient detoxification in HIV-positive opioid and/or cocaine-dependent patients.. <i>Experimental and Clinical Psychopharmacology</i> , 2014, 22, 75-85.	1.3	5
91	Association of patterns of methadone use with antiretroviral therapy discontinuation: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2015, 15, 537.	1.3	13
92	The influence of depressive symptoms and substance use on adherence to antiretroviral therapy. A cross-sectional prevalence study. <i>Sao Paulo Medical Journal</i> , 2015, 133, 179-186.	0.4	19
93	Impact of cocaine abuse on HIV pathogenesis. <i>Frontiers in Microbiology</i> , 2015, 6, 1111.	1.5	51

#	ARTICLE	IF	CITATIONS
94	Informal HIV Caregiver Proxy Reports of Care Recipients' Treatment Adherence: Relationship Factors Associated with Concordance with Recipients' Viral Suppression. <i>AIDS and Behavior</i> , 2015, 19, 2123-2129.	1.4	9
95	Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort. <i>AIDS and Behavior</i> , 2015, 19, 1089-1097.	1.4	9
96	Cocaine modulates HIV-1 integration in primary CD4+ T cells: implications in HIV-1 pathogenesis in drug-abusing patients. <i>Journal of Leukocyte Biology</i> , 2015, 97, 779-790.	1.5	28
97	Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 1128-1136.	0.6	37
98	Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the S <sub>wiss</sub> HIV Cohort Study. <i>HIV Medicine</i> , 2015, 16, 137-151.	1.0	38
99	Association of injection drug use with incidence of HIV-associated non-AIDS-related morbidity by age, 1995-2014. <i>Aids</i> , 2016, 30, 1447-1455.	1.0	13
100	The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 728-739.	1.0	9
101	Assessing Problematic Substance Use in HIV Care: Which Questions Elicit Accurate Patient Disclosures?. <i>Journal of General Internal Medicine</i> , 2016, 31, 1141-1147.	1.3	7
102	Recent Tobacco Smoking is Associated with Poor HIV Medical Outcomes Among HIV-Infected Individuals in New York. <i>AIDS and Behavior</i> , 2016, 20, 1722-1729.	1.4	47
103	Drug use among HIV+ adults aged 50 and older: findings from the GOLD II study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1373-1377.	0.6	24
104	Capsule Commentary on Callon et al., Assessing Problematic Substance Use in HIV Care: Which Questions Elicit Accurate Patient Disclosures?. <i>Journal of General Internal Medicine</i> , 2016, 31, 1214-1214.	1.3	0
105	Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study. <i>AIDS Research and Therapy</i> , 2016, 13, 26.	0.7	15
106	A longitudinal, HIV care continuum. <i>Aids</i> , 2016, 30, 2227-2234.	1.0	49
107	A qualitative study of barriers to and facilitators of optimal engagement in care among PLWH and substance use/misuse. <i>BMC Research Notes</i> , 2016, 9, 229.	0.6	36
108	Reducing non-injection drug use in HIV primary care: A randomized trial of brief motivational interviewing, with and without HealthCall, a technology-based enhancement. <i>Journal of Substance Abuse Treatment</i> , 2017, 74, 71-79.	1.5	24
109	HIV, Tat and dopamine transmission. <i>Neurobiology of Disease</i> , 2017, 105, 51-73.	2.1	52
110	Seeking Safety Group Therapy for Co-Occurring Substance Use Disorder and PTSD among Transgender Women Living with HIV: A Pilot Study. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 344-351.	1.0	33
111	Cocaine-using substance abuse treatment patients with and without HIV respond well to contingency management treatment. <i>Journal of Substance Abuse Treatment</i> , 2017, 77, 21-25.	1.5	8

#	ARTICLE	IF	CITATIONS
112	Alcohol and substance use diagnoses among HIV-positive patients receiving care in NYC clinic settings. <i>Drug and Alcohol Dependence</i> , 2017, 180, 62-67.	1.6	13
113	Compassionate love predicts long-term survival among people living with HIV followed for up to 17 years. <i>Journal of Positive Psychology</i> , 2017, , 1-10.	2.6	4
114	Enhancing patient navigation to improve intervention session attendance and viral load suppression of persons with HIV and substance use: a secondary post hoc analysis of the Project HOPE study. <i>Addiction Science &amp; Clinical Practice</i> , 2017, 12, 16.	1.2	19
115	Retention, Antiretroviral Therapy Use and Viral Suppression by History of Injection Drug Use Among HIV-Infected Patients in an Urban HIV Clinical Cohort. <i>AIDS and Behavior</i> , 2017, 21, 1016-1024.	1.4	30
116	Impact of illicit opioid use on T cell subsets among HIV-infected adults. <i>PLoS ONE</i> , 2017, 12, e0176617.	1.1	4
117	Barriers and facilitators of the HIV care continuum in Southern New England for people with drug or alcohol use and living with HIV/AIDS: perspectives of HIV surveillance experts and service providers. <i>Addiction Science &amp; Clinical Practice</i> , 2017, 12, 24.	1.2	24
118	Patterns of Substance Use and Arrest Histories Among Hospitalized HIV Drug Users: A Latent Class Analysis. <i>AIDS and Behavior</i> , 2018, 22, 2757-2765.	1.4	11
119	Measurement of Current Substance Use in a Cohort of HIV-Infected Persons in Continuity HIV Care, 2007-2015. <i>American Journal of Epidemiology</i> , 2018, 187, 1970-1979.	1.6	20
120	Chronic Pain Predicting Reciprocity of Support Among Vulnerable, Predominantly African-American Persons Living with HIV/AIDS. <i>AIDS and Behavior</i> , 2018, 22, 2002-2007.	1.4	6
121	Substance use Patterns and HIV-1 RNA Viral Load Rebound among HIV-Positive Illicit Drug users in a Canadian Setting. <i>Antiviral Therapy</i> , 2019, 24, 19-25.	0.6	23
122	Prevalence and Associations of Illicit Drug and Polydrug Use in People Living with HIV in Vienna. <i>Scientific Reports</i> , 2018, 8, 8046.	1.6	17
123	Strategies for improving the lives of US women aged 40 and above living with HIV/AIDS: an evidence map. <i>Systematic Reviews</i> , 2018, 7, 25.	2.5	4
124	Self-efficacy and ability to read as factors associated with antiretroviral therapy adherence in an HIV-infected population. <i>International Journal of STD and AIDS</i> , 2018, 29, 1154-1164.	0.5	4
125	HIV-1 infection alters energy metabolism in the brain: Contributions to HIV-associated neurocognitive disorders. <i>Progress in Neurobiology</i> , 2019, 181, 101616.	2.8	38
126	Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. <i>BMC Health Services Research</i> , 2019, 19, 862.	0.9	26
127	Associations between drug use patterns and viral load suppression among HIV-positive individuals who use support services in New York City. <i>Drug and Alcohol Dependence</i> , 2019, 197, 15-21.	1.6	14
128	The prevalence and patterns of substance use by birth cohort among HIV-positive adults in Florida. <i>Aging and Mental Health</i> , 2019, 23, 515-523.	1.5	4
129	The role of catecholamines in HIV neuropathogenesis. <i>Brain Research</i> , 2019, 1702, 54-73.	1.1	40



#	ARTICLE	IF	CITATIONS
130	Self-reported Cannabis Use and Changes in Body Mass Index, CD4 T-Cell Counts, and HIV-1 RNA Suppression in Treated Persons with HIV. <i>AIDS and Behavior</i> , 2020, 24, 1275-1280.	1.4	8
131	Increases in compulsivity, inflammation, and neural injury in HIV transgenic rats with escalated methamphetamine self-administration under extended-access conditions. <i>Brain Research</i> , 2020, 1726, 146502.	1.1	17
132	Longitudinal patterns of illicit drug use, antiretroviral therapy exposure and plasma HIV-1 RNA viral load among HIV-positive people who use illicit drugs. <i>Aids</i> , 2020, 34, 1389-1396.	1.0	21
133	HIV Neuropathogenesis in the Presence of a Disrupted Dopamine System. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 729-742.	2.1	27
134	Methadone Inhibits Viral Restriction Factors and Facilitates HIV Infection in Macrophages. <i>Frontiers in Immunology</i> , 2020, 11, 1253.	2.2	9
135	HIV screening in emergency departments: Linkage works but what about retention?. <i>Academic Emergency Medicine</i> , 2021, 28, 913-917.	0.8	5
136	Dental Care Utilization of Hospitalized Persons Living with HIV and Substance Use. <i>Journal of Community Health</i> , 2021, 46, 557-564.	1.9	2
137	Opioid use disorder and HIV. , 2021, , 51-75.		0
138	Prevalence and longitudinal correlates of recent exposure to fentanyl among HIV-positive people who use unregulated drugs during a community-wide overdose crisis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1-9.	0.6	2
139	Self-efficacy as a mediator of patient navigation interventions to engage persons living with HIV and substance use. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108567.	1.6	1
140	A "Drug-Dependent" Immune System Can Compromise Protection against Infection: The Relationships between Psychostimulants and HIV. <i>Viruses</i> , 2021, 13, 722.	1.5	1
141	Mini-review: The therapeutic role of cannabinoids in neuroHIV. <i>Neuroscience Letters</i> , 2021, 750, 135717.	1.0	14
142	Assessing combinatorial effects of HIV infection and former cocaine dependence on cognitive control processes: A high-density electrical mapping study of response inhibition. <i>Neuropharmacology</i> , 2021, 195, 108636.	2.0	10
143	Understanding the HIV/AIDS Epidemic in the United States" The Role of Syndemics in Shaping the Public's Health. <i>Social Disparities in Health and Health Care</i> , 2016, , 1-17.	0.0	2
145	Substance Use Treatment in the Era of New HIV Prevention Technologies. , 2014, , 161-177.		0
147	Substance Use and Co-occurring Infections (Including Immunology). , 2021, , 1177-1190.		0
149	Impact of substance abuse on treatment adherence. <i>Psychiatry</i> , 2008, 5, 16.	0.3	0
150	Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. <i>Addiction Science &amp; Clinical Practice</i> , 2021, 16, 67.	1.2	3

#	ARTICLE	IF	CITATIONS
151	Crossroads of Drug Abuse and HIV Infection: Neurotoxicity and CNS Reservoir. <i>Vaccines</i> , 2022, 10, 202.	2.1	5
152	Escalated (Dependent) Oxycodone Self-Administration Is Associated with Cognitive Impairment and Transcriptional Evidence of Neurodegeneration in Human Immunodeficiency Virus (HIV) Transgenic Rats. <i>Viruses</i> , 2022, 14, 669.	1.5	4
156	Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. <i>Antiviral Therapy</i> , 2008, 13, 25-36.	0.6	222
157	Cultural adaptation and psychometric properties of the Substance Abuse Self-Stigma Scale among Latinos with substance use disorders: An effective screening tool for correctional and community settings.. <i>Stigma and Health</i> , 2022, 7, 347-357.	1.2	2
158	Virally Suppressed People Living with HIV Who Use Opioids Have Diminished Latency Reversal. <i>Viruses</i> , 2023, 15, 415.	1.5	4
161	Targeting the endocannabinoid system in HAND. , 2024, , 539-556.		0
162	NeuroHIV in the context of opioid use disorder. , 2024, , 459-477.		0
163	The effect of substance misuse on HIV persistence in the CNS. , 2024, , 399-437.		0